Overview

IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Status:
RECRUITING

Trial end date:
2026-12-24

Target enrollment:

Participant gender:

Summary

This is a multicenter, randomized, double-blind, phase II clinical study to evaluate the efficacy and safety of IN10018 in combination with PLD vs. placebo in combination with PLD in subjects with platinum-resistant recurrent ovarian cancer (including fallopian tube and primary peritoneal cancers).

Phase:

PHASE2

Details

Lead Sponsor:

InxMed (Shanghai) Co., Ltd.

Treatments:

1-dodecylpyridoxal
liposomal doxorubicin